Reading VEEV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VEEV free→Reading VEEV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VEEV free→NYSEHealth CareHealth Information ServicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but risk is elevated and the sector backdrop is a headwind. Earnings quality is neutral, and compared with sector peers, VEEV is above typical. Peer multiples imply a price about 24% below where it trades (it looks expensive on this basis); the read is fair, priced roughly in line with peer multiples. This assessment hinges on guidance changes, as a cut could negatively impact estimates, while positive trends from sector bellwethers could provide support. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $162.22. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $162 VEEV trades at 19× p/e — 1.3× the 15× p/e peer median. The market is re-rating it beyond its own range; our $124 fair value is low-confidence here. Analysts: $165–$320. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 31% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.77x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Not enough signal yet.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $2.19 → $2.22 (+1.7% / 30d). 23 raised, 3 cut, 24 covering analysts.
0 upgrades, 0 downgrades / 30d, 17 maintained. 74% of analysts rate Buy.
12 PT revisions / 30d. Avg target 29.9% above current price.
0 positive, 0 negative / 30d.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$136.
How much price usually moves either way.
On a bad day, this stock has moved -$370.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,055.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This guidance is key to understanding Veeva's growth plans. Strong guidance could boost investor confidence.
Confirms:Watch for management to raise revenue growth guidance for fiscal year 2027. This is above current expectations.
Disproves:Watch for management to lower revenue growth guidance for fiscal year 2027. This is below current expectations.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for VEEV yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On June 3, 2026, Veeva Systems Inc. (“Veeva”) issued a press release announcing its results for its first quarter ended April 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$165.00 – $320.00 (median $227.50) · 14 analysts · as of 2026-06-04
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2026-Q1, 2026-Q2, 2026-Q3, 2027-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
VEEV Veeva Systems | Above typical Show detailsSector percentile: 79 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 72 of 100 | — | elevated |
DOCS Doximity | Above typical Show detailsSector percentile: 80 of 100 | full | high |
TXG 10X Genomics, Inc. | Typical Show detailsSector percentile: 44 of 100 | expensive | elevated |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Met or beat guidance 100% of the last 2 guided quarters · 6.1% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Veeva aims for total revenues between $3,635 and $3,645 million for fiscal year 2027.
Veeva continues to focus on quarterly revenue growth, achieving $835.95 million in 2026-Q4.
Veeva projects non-GAAP EPS of approximately $9.05 for fiscal year 2027.
Why it matters: Quarterly growth shows how well Veeva is performing. Strong results can attract more investors.
Confirms:Quarterly revenue growth exceeds 10% year over year.
Disproves:Quarterly revenue growth falls below 5% year over year.
Why it matters: Meeting or exceeding revenue guidance shows strong demand and growth momentum for Veeva.
Confirms:Total revenues reported for Q2 are at least $905 million.
Disproves:Total revenues reported for Q2 fall below $902 million.
Why it matters: EPS guidance helps investors gauge profit potential. Strong EPS guidance can lead to positive market reactions.
Confirms:Watch for management to raise non-GAAP EPS guidance for fiscal year 2027. This is above current expectations.
Disproves:Watch for management to lower non-GAAP EPS guidance for fiscal year 2027. This is below current expectations.
Why it matters: Updates on Veeva AI will show how well they are transforming their offerings and meeting customer needs.
Confirms one read:They announced that Vault AI is now used in all applications.
Confirms the other:Delay in the rollout of Vault AI or negative feedback from early adopters.
Why it matters: Earnings per share above this level shows strong profit and good operations.
Confirms:Non-GAAP EPS reported for Q2 is at least $2.22.
Disproves:Non-GAAP EPS reported for Q2 is below $2.21.
Why it matters: A drop in sector growth could signal broader issues. It may affect Veeva's performance and outlook.
Confirms:Sector revenue growth falls below its median of 10%.
Disproves:Sector revenue growth remains above its median of 10%.